Premium
The effectiveness of Clostridium botulinum toxin A (Dysport ® , AbobotulinumtoxinA) in the management of temporomandibular dysfunction (TMD) and a small number of other maxillofacial conditions; an open cohort study
Author(s) -
White S.,
Ahmed B.,
Ondhia A.
Publication year - 2018
Publication title -
oral surgery
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.156
H-Index - 11
eISSN - 1752-248X
pISSN - 1752-2471
DOI - 10.1111/ors.12338
Subject(s) - medicine , retrospective cohort study , cohort , botulinum toxin , cohort study , open bite , surgery , dentistry , malocclusion
Aim To examine the effectiveness of Botulinum Toxin Type A (Dysport ® ) in treating TMD and a small number of other maxillofacial conditions in our department. The secondary aim was to identify any predictors of outcome. Methods A retrospective open cohort study[1][Dekkers OM, 2012]; data abstraction from 38 case files. Results The effectiveness of Dysport ® in treating TMD lies between 60% and 79%. Sixty‐nine per cent of patients who obtained benefit received repeat treatment. Conclusions Our findings suggest Dysport ® is a safe, well‐tolerated and effective treatment for TMD and Masseteric hypertrophy.